• Cancel
    Date：2021-02

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2021-02
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=519

    Guangzhou Weiyuan (Vision Medicals) Gene Technology Co., Ltd. (hereinafter referred to as “Vision Medicals” or the “Company”), a leader in the infection precision medicine industry, recently announced the completion of a Series B financing round of several hundred million RMB. This round of financing was led by CDH Investment, with participation from CICC Qichen and existing shareholders, Volcanics Venture and Cash Capital. This round of financing will primarily be used for funding product R&D, establishing a clinical testing network, driving product registration efforts, constructing manufacturing facilities, improving clinical services, and increasing brand marketing. CEC Capital Group served as the exclusive financial advisor of Vision Medicals in this transaction.

  • Cancel
    Date：2021-02

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2021-01

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-12
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=535

    CEC Capital Group serves as exclusive financial advisor Beijing Haosi (Health) Biotechnology Co., Ltd. (hereinafter referred to as "Haosi Bio" or the "Company"), a leading provider of solutions for clinical mass spectrometry detection, today announced th

  • Cancel
    Date：2020-12

    CEC Capital Served as Financial Advisor

  • Cancel
    Date：2020-11
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=516

    Huiyihuiying (the “Company”) a leader in medical imaging artificial intelligence, announced that it has successfully completed its latest round (Series C2) of hundreds of millions of RMB in financing, one of the largest financings in the healthcare AI industry in China. This round of financing included new investors Shougang Fund, Sinopharm Junbai, and Kunjian Xintai, and existing shareholders including CDH Investments, Datai Capital, and Lanchi Ventures. CEC Capital Group served as the exclusive financial advisor of Huiyihuiying in this transaction.

  • Cancel
    Date：2020-10

    CEC Capital Group serves as exclusive financial advisor

  • Cancel
    Date：2020-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=504

    3DMed Diagnostic (the “Company”), a leader in the field of accurate tumor diagnosis in China, recently completed a financing of RMB 280 million for its diagnostics business segment. The financing round was jointly led by China Resources Pharmaceutical Industry Investment Fund, Shandong Luxin High-tech Industry Co. Ltd., and the Shandong Transportation Industry Development Fund. After serving as exclusive financial advisor for 3D Medicines, the parent company of 3DMed Diagnostic, in its first round of financing, CEC Capital Group continued to serve as exclusive financial advisor for the first round of financing for 3DMed Diagnostic after it was spun-off from the parent company.